title: One-step multiplex real-time RT-PCR assay for detecting and genotyping wild-type group A rotavirus strains and vaccine strains (Rotarix® and RotaTeq®) in stool samples.
abstract: Background. Group A rotavirus (RVA) infection is the major cause of acute gastroenteritis (AGE) in young children worldwide. Introduction of two live-attenuated rotavirus vaccines, RotaTeq® and Rotarix®, has dramatically reduced RVA associated AGE and mortality in developed as well as in many developing countries. High-throughput methods are needed to genotype rotavirus wild-type strains and to identify vaccine strains in stool samples. Quantitative RT-PCR assays (qRT-PCR) offer several advantages including increased sensitivity, higher throughput, and faster turnaround time. Methods. In this study, a one-step multiplex qRT-PCR assay was developed to detect and genotype wild-type strains and vaccine (Rotarix® and RotaTeq®) rotavirus strains along with an internal processing control (Xeno or MS2 RNA). Real-time RT-PCR assays were designed for VP7 (G1, G2, G3, G4, G9, G12) and VP4 (P[4], P[6] and P[8]) genotypes. The multiplex qRT-PCR assay also included previously published NSP3 qRT-PCR for rotavirus detection and Rotarix® NSP2 and RotaTeq® VP6 qRT-PCRs for detection of Rotarix® and RotaTeq® vaccine strains respectively. The multiplex qRT-PCR assay was validated using 853 sequence confirmed stool samples and 24 lab cultured strains of different rotavirus genotypes. By using thermostable rTth polymerase enzyme, dsRNA denaturation, reverse transcription (RT) and amplification (PCR) steps were performed in single tube by uninterrupted thermocycling profile to reduce chances of sample cross contamination and for rapid generation of results. For quantification, standard curves were generated using dsRNA transcripts derived from RVA gene segments. Results. The VP7 qRT-PCRs exhibited 98.8-100% sensitivity, 99.7-100% specificity, 85-95% efficiency and a limit of detection of 4-60 copies per singleplex reaction. The VP7 qRT-PCRs exhibited 81-92% efficiency and limit of detection of 150-600 copies in multiplex reactions. The VP4 qRT-PCRs exhibited 98.8-100% sensitivity, 100% specificity, 86-89% efficiency and a limit of detection of 12-400 copies per singleplex reactions. The VP4 qRT-PCRs exhibited 82-90% efficiency and limit of detection of 120-4000 copies in multiplex reaction. Discussion. The one-step multiplex qRT-PCR assay will facilitate high-throughput rotavirus genotype characterization for monitoring circulating rotavirus wild-type strains causing rotavirus infections, determining the frequency of Rotarix® and RotaTeq® vaccine strains and vaccine-derived reassortants associated with AGE, and help to identify novel rotavirus strains derived by reassortment between vaccine and wild-type strains.
authors.affiliation: Division of Viral Diseases, Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention , Atlanta, Georgia , United States of America.
authors.forename: Rashi
authors.initials: R
authors.lastname: Gautam
authors.affiliation: Division of Viral Diseases, Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention , Atlanta, Georgia , United States of America.
authors.forename: Slavica
authors.initials: S
authors.lastname: Mijatovic-Rustempasic
authors.affiliation: Division of Viral Diseases, Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention , Atlanta, Georgia , United States of America.
authors.forename: Mathew D
authors.initials: MD
authors.lastname: Esona
authors.affiliation: Division of Viral Diseases, Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention , Atlanta, Georgia , United States of America.
authors.forename: Ka Ian
authors.initials: KI
authors.lastname: Tam
authors.affiliation: Division of Viral Diseases, Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention , Atlanta, Georgia , United States of America.
authors.forename: Osbourne
authors.initials: O
authors.lastname: Quaye
authors.affiliation: Division of Viral Diseases, Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention , Atlanta, Georgia , United States of America.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Bowen
keywords: Gastroenteritis; Multiplex qRT-PCR; RotaTeq®; Rotarix®; Rotavirus genotyping
references.citation: J Virol Methods. 2006 Nov;137(2):280-6
references.pmid: 16890998
references.citation: Lancet Infect Dis. 2012 Feb;12(2):136-41
references.pmid: 22030330
references.citation: Vaccine. 2011 Nov 28;29(51):9508-13
references.pmid: 22008819
references.citation: J Clin Microbiol. 2001 Oct;39(10):3796-8
references.pmid: 11574622
references.citation: J Med Virol. 2008 Aug;80(8):1489-96
references.pmid: 18551614
references.citation: Lett Appl Microbiol. 2011 Mar;52(3):239-44
references.pmid: 21219370
references.citation: J Clin Microbiol. 2013 Feb;51(2):472-80
references.pmid: 23175269
references.citation: J Clin Virol. 2004 Dec;31(4):259-65
references.pmid: 15494266
references.citation: J Infect Dis. 2012 Aug 1;206(3):377-83
references.pmid: 22615314
references.citation: J Clin Microbiol. 2002 Jul;40(7):2398-407
references.pmid: 12089254
references.citation: J Infect Dis. 2009 Nov 1;200 Suppl 1:S228-33
references.pmid: 19817602
references.citation: J Virol Methods. 2015 Mar;213:157-63
references.pmid: 25526999
references.citation: Future Microbiol. 2009 Dec;4(10):1303-16
references.pmid: 19995190
references.citation: J Clin Virol. 2011 Apr;50(4):308-13
references.pmid: 21256076
references.citation: J Infect Dis. 2012 Oct;206(8):1275-9
references.pmid: 22872730
references.citation: J Allergy Clin Immunol. 2009 Sep;124(3):600
references.pmid: 19660805
references.citation: J Clin Microbiol. 2009 Sep;47(9):2704-12
references.pmid: 19553575
references.citation: Arch Virol. 2011 Aug;156(8):1397-413
references.pmid: 21597953
references.citation: J Clin Microbiol. 1992 Jun;30(6):1365-73
references.pmid: 1320625
references.citation: J Clin Microbiol. 2006 Sep;44(9):3189-95
references.pmid: 16954246
references.citation: J Virol Methods. 2012 Mar;180(1-2):49-53
references.pmid: 22245180
references.citation: Lancet Infect Dis. 2008 Oct;8(10):642-9
references.pmid: 18922486
references.citation: J Virol Methods. 2009 Feb;155(2):126-31
references.pmid: 18951923
references.citation: Infect Genet Evol. 2012 Aug;12(6):1282-94
references.pmid: 22487061
references.citation: BMC Microbiol. 2009 Nov 23;9:238
references.pmid: 19930627
references.citation: Vaccine. 2011 May 31;29(24):4151-5
references.pmid: 21477676
references.citation: Pediatr Infect Dis J. 2011 Jan;30(1 Suppl):S1-5
references.pmid: 21183833
references.citation: Emerg Infect Dis. 2013 Nov;19(11):1843-6
references.pmid: 24188273
references.citation: Pediatr Infect Dis J. 2012 Sep;31(9):992-4
references.pmid: 22581224
references.citation: J Clin Microbiol. 2008 Aug;46(8):2547-54
references.pmid: 18524966
references.citation: J Clin Microbiol. 1990 Feb;28(2):276-82
references.pmid: 2155916
references.citation: J Med Virol. 2004 May;73(1):118-22
references.pmid: 15042658
references.citation: J Virol. 2006 Apr;80(8):3801-10
references.pmid: 16571797
references.citation: J Clin Microbiol. 1994 Jul;32(7):1820-2
references.pmid: 7929782
references.citation: N Engl J Med. 2010 Jan 28;362(4):314-9
references.pmid: 20107217
references.citation: Methods Mol Med. 2000;34:189-216
references.pmid: 21318861
references.citation: J Clin Microbiol. 2010 May;48(5):1859-65
references.pmid: 20220154
references.citation: J Clin Microbiol. 2005 Dec;43(12):5876-80
references.pmid: 16333070
references.citation: Hum Vaccin Immunother. 2014;10(3):767-77
references.pmid: 24342877
references.citation: J Gen Virol. 2013 Jan;94(Pt 1):136-42
references.pmid: 23052396
references.citation: Vaccine. 2012 Apr 27;30 Suppl 1:A122-30
references.pmid: 22520121
references.citation: J Clin Microbiol. 2013 Sep;51(9):3047-54
references.pmid: 23850952
references.citation: Pediatrics. 2010 Feb;125(2):e438-41
references.pmid: 20100758
references.citation: Virol J. 2011 Feb 10;8:63
references.pmid: 21310042
references.citation: Expert Rev Vaccines. 2012 Nov;11(11):1311-4
references.pmid: 23249230
references.citation: J Virol Methods. 2002 Aug;105(1):99-103
references.pmid: 12176146
references.citation: J Virol Methods. 2013 Dec;194(1-2):242-9
references.pmid: 24036075
references.citation: Rev Med Virol. 2004 Mar-Apr;14(2):71-82
references.pmid: 15027000
references.citation: J Clin Virol. 2007 Aug;39(4):318-21
references.pmid: 17604686
references.citation: Nucleic Acids Res. 1988 Nov 25;16(22):10881-90
references.pmid: 2849754
references.citation: Epidemiol Infect. 2011 Jun;139(6):895-909
references.pmid: 20707941